التفاصيل البيبلوغرافية
| العنوان: |
The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. |
| المؤلفون: |
Hong, J. Y.1, Hong, M. E.2, Choi, M. K.1, Kim, Y. S.3, Chang, W.1, Maeng, C. H.4, Park, S.1, Lee, S. J.1, Do, I.-G.5, Jo, J.-S.5, Jung, S. H.6, Kim, S. J.1, Ko, Y. H.2, Kim, W. S.1 |
| المصدر: |
Annals of Oncology. Jan2014, Vol. 25 Issue 1, p182-188. 7p. |
| مصطلحات موضوعية: |
*GENE expression, *B cell lymphoma, *SERINE/THREONINE kinases, *LACTATE dehydrogenase, *CANCER cell proliferation, *HEALTH outcome assessment, *MEDICAL statistics |
| مستخلص: |
High p-AKT expression in DLBCL is associated with distinctive clinical features and poor prognosis. More effective treatment option should be developed for this subset of DLBCL patients and targeting PI3K/AKT pathway may be a promising therapeutic strategy .Background Oncogenic phosphatidylinositol-3-kinase/serine-threonine kinase (PI3K/AKT) pathway plays a critical role in cell proliferation and growth. Phosphorylated AKT (p-AKT) has been reported to be abnormally overexpressed and to have poor prognostic impact in solid tumors. Patients and methods To define the clinical implications of p-AKT expression in diffuse large B-cell lymphoma (DLBCL), we calculated arbitrary units (AUs) by multiplying the intensity and the proportion of p-AKT expression and investigated the impact of p-AKT expression on clinical outcomes. We assessed 262 patients with DLBCL. Based on a cutoff value of the upper limit of the third quartile of AUs, 56 patients were classified as high p-AKT and the remaining 206 patients were classified as low p-AKT. Results The high p-AKT group was closely associated with more advanced stage (stage III–IV, P = 0.02), two or more extranodal involvement (P = 0.03), lactic dehydrogenase elevation (P = 0.03), higher International Prognostic Index risk groups (high intermediate/high, P = 0.02), and the presence of B-symptoms (P = 0.01). The high p-AKT group showed substantially worse overall survival (OS) (median OS, 115.0 months versus not reached, P = 0.004) and progression-free survival (PFS) (median PFS, 25.5 versus 105.8 months, P = 0.019) compared with the low p-AKT group. Multivariate analysis revealed that high p-AKT expression retained its significant poor prognostic impact for OS (hazard ratio 1.7; 95% confidence interval, 1.0–2.7; P = 0.031). The subgroup with high p-AKT expression and concurrent Epstein–Barr virus positivity showed worst prognosis with the median OS and PFS of 15.2 and 7.4 months. Conclusion DLBCL patients with high p-AKT expression showed distinct clinical features and followed a more rapidly deteriorating clinical course with worse OS and PFS. Thus, a more effective treatment option should be developed for this subset of DLBCL patients, and targeting PI3K/AKT pathway may be a promising therapeutic strategy. Trial registration This study is registered with ClinicalTrials.gov, number NCT01789060. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder